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Summary
The oligosaccharide antibiotic avilamycin A is com-
posed of a polyketide-derived dichloroisoeverninic
acid moiety attached to a heptasaccharide chain con-
sisting of six hexoses and one unusual pentose moi-
ety. We describe the generation of mutant strains of
the avilamycin producer defective in different sugar
biosynthetic genes. Inactivation of two genes (aviD
and aviE2) resulted in the breakdown of the avilamycin
biosynthesis. In contrast, avilamycin production was
not influenced in an aviP mutant. Inactivation of
aviGT4 resulted in a mutant that accumulated a novel
avilamycin derivative lacking the terminal eurekanate
residue. Finally, AviE2 was expressed in Escherichia
coli and the gene product was characterized biochemi-
cally. AviE2 was shown to convert UDP-D-glucuronic
acid to UDP-D-xylose, indicating that the pentose res-
idue of avilamycin A is derived from D-glucose and
not from D-ribose. Here we report a UDP-D-glucuronic
acid decarboxylase in actinomycetes.
Introduction
Avilamycins are oligosaccharide antibiotics isolated
from Streptomyces viridochromogenes Tu¨57 (S. virido-
chromogenes Tu¨57) [1] (Figure 1). Avilamycin A, the
main compound produced by the strain was shown to
be active against many Gram-positive bacteria, includ-
ing emerging problem organisms such as vancomycin-
resistant enterococci, methicillin-resistant staphylococci,
and penicillin-resistant pneumococci [2]. Evernimicin
(Ziracin), which is structurally very similar to avilamycin,
was under investigation for approval by Schering-
Plough. Due to side effects and its poor water solubility,
further development was stopped in 2000 [3]. Evernimi-
cin and avilamycin were shown to inhibit protein biosyn-
thesis by binding to the 50S ribosomal subunit of the
bacterial ribosomes [4–6]. It was suggested that they in-
*Correspondence: glaser@ch.tum.de (S.J.G.), andreas.bechthold@
pharmazie.uni-freiburg.de (A.B.)
3These authors contributed equally to this work.teract with the ribosomal A-site and interfere with initia-
tion factor IF2 and tRNA binding.
Recently, we reported the sequence of the complete
biosynthetic gene cluster for avilamycin A [7]. Based
on sequence similarities of the deduced proteins to en-
zymes of known functions, putative biosynthetic path-
ways to each sugar were proposed. Gene disruption
experiments with putative methyltransferase genes [2]
have led to new avilamycins with enhanced water solu-
bility (named gavibamycins) (Figure 1) and after deletion
of aviB1 and aviO2 an avilamycin derivative (gaviba-
mycin O) was obtained lacking the acetyl residue at
position C-4 of the eurekanate moiety of avilamycin
A [8].
It is most likely that the biosynthesis of avilamycin A
starts with the formation of the unusual disaccharide
consisting of the pentose L-lyxose and the hexose
D-mannose. The attachment of the progenitor of eure-
kanate to the C-4 position is a further plausible step to-
ward the formation of the heptasaccharide side chain.
However, insights regarding early steps in the biosyn-
thesis of avilamycin A are sparse.
Our recent elucidation of the avilamycin gene locus
revealed several deoxy sugar biosynthetic genes and
four glycosyltransferase genes. Based on sequence ho-
mologies AviD, a putative dNDP-glucose synthetase,
was discussed to be the entrance enzyme of the
D-olivose and 2-deoxy-D-evalose pathway. AviP, a pu-
tative phosphatase, was thought to be the first enzyme
of the pathway leading to L-lyxose and AviE2, a putative
4,6-dehydratase, leading to eurekanate.
In order to gain insights into the biosynthesis of the
avilamycin molecule, we now report classical feed-
ing experiments, the generation of four mutants of the
avilamycin producer with deletion in different sugar bio-
synthetic and glycosyltransferase genes and the over-
expression of aviE2 in E. coli.
Our results indicate that L-lyxose derives from D-glu-
cose by decarboxylation and that AviGT4 is a glycosyl-
transferase involved in the formation of the orthoester
linkage between L-lyxose and the eurekanate residue.
Results and Discussion
Feeding of Labeled D-Glucose
Labeled glucose (U-13C glucose, 1-13C glucose) was
added to the culture medium inoculated with S. virido-
chromogenes Tu¨57. Avilamycin A was isolated by
reverse phase chromatography and preparative high
pressure liquid chromatography-mass spectrometry
(HPLC-MS). In the nuclear magnetic resonance (NMR)
spectra of the labeled compound obtained by feeding
1-13C glucose (Figure 2a), the signal volumes of all car-
bons in the C-1 positions are identical (within error limits
of 11%) and w8-fold larger than the signal volumes of
carbons at other positions. This increased occurrence
of 13C at the C-1 positions indicates usage of D-glucose
as a precursor for all components, which was in con-
trast to the assumption that ribose-5-phosphate is the
precursor of L-lyxose [7].
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bamycin DerivativesThe NMR analysis of the U-13C glucose feeding ex-
periment (Figure 2b) allowed to identify D-glucose as
the source of the methyl group at position C-5 of the
eurekanate residue. The signal of 35 (see Figure 1 for
nomenclature) is representative for a methyl group de-
rived directly from D-glucose, whereas position 27 is
an example for a CH3-group attached to the sugar ring
at a later stage of the biosynthesis. (This has been
shown by 13C-labeled L-methionine feeding experi-
ments described in [7].) Integration of a variety of sig-
nals (among them the ones of positions 35 and 58)
showed that the average degree of 13C-labeling was
w20%, whereas position 27 was labeled to only w8%,
indicating that position 58 is derived directly from D-glu-
cose. The shapes of the signals prove this assumption.
The signals of 35 and 58 show small, uncoupled singlets
and large doublets caused by the 1J13C,13C couplings to
the adjacent carbons in the sugar rings (positions 33
and 57, respectively). Thus, a labeled methyl group
has a very high probability (>90%) of being connected
to a 13C-atom. Because of the average degree of 13C-
labeling (w20%), this is possible only if the complete
C6 scaffold of the U-
13C glucose, including the methyl
group, is inserted as a whole during biosynthesis. On
the other hand, the signal of position 27 shows a large
singlet and a small doublet. For this position, therefore,the probability of being connected to a 13C in the ring
(at position 24) is in the range of the average degree
of labeling, confirming the subsequent addition of the
methyl group to the U-13C glucose scaffold.
Because evernimicin, another orthosomycin antibi-
otic, lacks a methyl group at position C-5 of eurekanate,
different biosynthetic pathways to both antibiotics have
to be discussed.
Generation of S. viridochromogenes Tu¨57DaviD,
S. viridochromogenes GW4DaviP,
S. viridochromogenes GW4DaviE2,
and S. viridochromogenes GW4DaviGT4
For generation of mutants, gene inactivation experi-
ments were carried out. As hosts we used S. viridochro-
mogenesTu¨57 andS. viridochromogenesGW4, a mutant
lacking the methyltransferase gene aviG4 [7]. Plasmids
were constructed as described in Experimental Proce-
dures, allowing the replacement of the wild-type gene
by a mutated allele in S. viridochromogenes Tu¨57. The
deletions within the genes were confirmed by polymer-
ase chain reaction (PCR) (aviD, aviP, aviE2, aviGT4)
and by Southern hybridization (aviD, aviP, aviE2). PCR
fragments obtained from double crossover mutants
(S. viridochromogenes Tu¨57DaviD, S. viridochromo-
genes GW4DaviP, S. viridochromogenes GW4DaviE2,Figure 2. Sections of the 13C-1D-NMR Spec-
trum
(A) Section of the 13C-1D-NMR spectrum
(1H-decoupled) of avilamycin after the feed-
ing experiment with 1-13C glucose showing
the signals of five partially labeled (10, 22,
29, 36, and 44) and three unlabeled (19, 25,
and 31) carbons. The numbering of the reso-
nances corresponds to Figure 1. Signals
marked with asterisks are impurities. The
chemical shifts for carbons 36 and 44 show
slight variations for avilamycin A, avilamycin
B and avilamycin C which were abundant at a ratio of approximately. 40:10:50 (determined by HPLC and NMR).
(B) Two sections of the 13C-1D-NMR spectrum (1H-decoupled) of the U-13C glucose feeding experiment comparing the signal of position 58
with the ones of 27 and 35 (see Figure 1 for nomenclature). The signal of 35 is representative for a methyl group derived directly from D-glucose
whereas position 27 is an example for a CH3-group attached to the sugar ring at a later stage of the biosynthesis [7].
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1139Figure 3. Region of the Avilamycin Biosyn-
thetic Gene Cluster Containing aviD, aviE2,
aviGT4, and aviP
Only genes investigated during this study
are shown as arrows. Fragments containing
each individual gene used for the generation
of inactivation constructs as well as impor-
tant restriction sites are indicated.and S. viridochromogenes GW4DaviGT4) using prim-
ers aviD-F2/aviD-R2, aviP-A/aviP-B, aviE2P-F/aviE2P-R,
and aviGT4-F2/aviGT4-R2, respectively, could not be di-
gested by SmaI, NotI, BamHI, and NotI, respectively (Fig-
ure 3), whereas the PCR fragments obtained from
S. viridochromogenes Tu¨57 and S. viridochromogenes
GW4 could be digested by the enzymes. To determine
clearly that the mutation event affected only the desired
genes and not other genes, aviE2 and aviGT4 were li-
gated behind the ermE* promoter of pSET-1cerm and
were introduced by protoplast transformation into the
corresponding mutants. Complementation of S. virido-
chromogenes Tu¨57DaviD was achieved by expression
of a 5 kb fragment containing aviD behind the native pro-
moter. Avilamycin (gavibamycin) production was re-
stored in each case.
Isolation and Identification of Avilamycin
Derivatives
S. viridochromogenes Tu¨57, S. viridochromogenes
GW4, S. viridochromogenes Tu¨57DaviD, S. viridochro-
mogenesGW4DaviP, S. viridochromogenesGW4DaviE2
and S. viridochromogenes GW4DaviGT4 were grown
under the conditions described in Experimental Proce-
dures. Extracts were analyzed by thin-layer chromatog-
raphy (TLC), HPLC-UV/Vis, and HPLC-ESI (electrospray
ionization)-MS. Avilamycin A and C were detected in
S. viridochromogenes Tu¨57 (wild-type strain), gaviba-
mycins A1 and A3 were detected in S. viridochromo-genes GW4 and S. viridochromogenes GW4DaviP. No
avilamycin derivative could be observed in S. virido-
chromogenes Tu¨57DaviD and in S. viridochromogenes
GW4DaviE2. The HPLC-ESI-MS analysis of the mutant
S. viridochromogenes GW4DaviGT4 revealed that none
of the gavibamycins typically found in S. viridochromo-
genes GW4 were produced. Instead, a novel compound
with the typical UV/Vis spectrum of the gavibamycin
chromophore was identified. Its molecular ion with m/z
1189 [M-H]2 displayed the diagnostic isotope pattern
distinctive for the double-chlorinated gavibamycins
(Figure 4). Hence, the compound was very likely a gavi-
bamycin derivative, referred to as gavibamycin P1. The
mass difference of 198 amu compared to gavibamycin
A1 (m/z 1387 [M-H]2) produced by S. viridochromo-
genes GW4 indicated a lacking eurekanate moiety, the
terminal residue of the oligosaccharide chain (Figure
4). To corroborate this structure, a comparative frag-
mentation analysis with an atmospheric pressure chem-
ical ionization (APCI) source was carried out with
gavibamycin A1 serving as reference. For this purpose,
gavibamycins P1 and A1 were purified from S. virido-
chromogenes GW4DaviGT4 and S. viridochromogenes
GW4, respectively. Subsequent fragmentation analysis
revealed an analogous fragmentation pattern for both
compounds in the negative ionization mode (Figure 4).
Two groups of fragments could be observed. First, frag-
ments with the isotope profile of the chlorinated orsel-
linic acid and equal mass between gavibamycin P1Figure 4. Mass Spectrometry of Gavibamycin A1 and P1
ESI-MS analysis yields the deprotonated molecule with m/z 1387 and m/z 1189, respectively. In both cases, the diagnostic isotope pattern
reflects the presence of the double-chlorinated orsellinic acid. APCI-MS analysis yields an analogous fragmentation pattern of both com-
pounds. The fragments labeled with an asterisk display the isotope pattern of the orsellinic acid. All further fragments differ in 198 amu be-
tween gavibamycin A1 and P1, representing the lacking terminal eurekanate residue in gavibamycin P1.
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Acid to UDP-D-Xylose by AviE2
The results of different incubations analyzed
by HPLC are shown as follows: (1) Incuba-
tion containing AviE2; (2) incubation contain-
ing enzyme eluted from a Ni-NTA column
obtained from E. coli cultures containing
pRSETB (vector without insert); (3) no en-
zyme. Chromatographic peaks correspond-
ing to NAD+ (A), UDP-GlcA (B), and UDP-D-
xylose (C) are indicated by arrows.and A1. Second, fragments that differed in 198 amu from
those derived from gavibamycin P1 displaying the lower
mass. These fragments represent a terminally shortened
oligosaccharide chain and therefore can plausibly ex-
plain the structure of a gavibamycin lacking the eureka-
nate residue (Figure 4).
Although it was expected that the aviD mutant would
not produce any avilamycin derivative, production of
avilamycins by the aviP mutant and nonproduction by
the aviE2 mutant were surprising results. We concluded
that AviP is not involved in the formation of the L-lyxose
moiety and that AviE2 is not an NDP-glucose 4,6-dehy-
dratase involved in the eurekanate biosynthesis.
AviGT4 Is Involved in the Formation of the Linkage
between L-Lyxose and Eurekanate
Because our data show that the derivative gavibamycin
P1 produced by S. viridochromogenes GW4DaviGT4
lacks the terminal eurekanate moiety and because
AviGT4 matches GTs that are involved in cell envelope
and lipopolysaccharide biosynthesis, we conclude
that AviGT4 is essential for the transfer of the eureka-
nate residue to the L-lyxose moiety. For now, we cannot
predict whether AviGT4 is responsible for the formation
of a ‘‘simple’’ glycosidic bond or whether it catalyzes the
entire formation of the orthoester. Results of the aviGT4
inactivation experiments revealed that the disaccharide
L-lyxose-eurekanate is not the starter molecule for avi-
lamycin A biosynthesis. It now seems likely that the avi-
lamycin biosynthesis begins within the formation of the
1/1 linked disaccharide D-mannopyranosyl-L-lyxose
instead.
AviE2, a Decarboxylase as Key Enzyme
for the Generation of L-Lyxose during Avilamycin
A Biosynthesis
Results of the knockout experiments prompted us to
perform a careful BLAST analysis of the encoded
AviE2. AviE2 is homologous to other enzymes that oxi-
dize the C-4 position of certain UDP-sugars, such as
UDP-galactose epimerase [9], dTDP-glucose-4,6-de-
hydratase [10], and eukaryotic UDP-glucuronic acid
(UDP-GlcA) decarboxylases [11, 12], all belonging to
the short chain dehydrogenase/reductase superfamily
[13, 14]. This group of proteins is characterized by high
structural similarity and the presence of specific se-quence motifs despite low overall sequence identity
[15]. AviE2 retains the glycine-rich NAD+ binding motif
GXXGXXG represented by amino acids G15GAG18FIG21.
A conserved acidic amino acid (D49 in AviE2) is also pres-
ent. This acidic amino acid interacts with adenine ribose
hydroxyl groups and is present in all NAD+ and FAD+
binding members of the SDR family [14]. The sequence
YXXXK, together with a conserved T/S residue, is re-
sponsible for the NAD+ dependent oxidation of a sugar
hydroxyl group at position C-4 in UDP-sugars, and these
motifs are also present in AviE2, represented by residues
T134 and Y163DEAK167. Serine and lysine are suggested
to activate tyrosine to abstract the C-4 proton to yield
a nucleotide-4-keto sugar intermediate [16]. A glutamate
D164 (prevents ring flipping) and an arginine R318 (respon-
sible for decarboxylation) are strictly conserved in UDP-
GlcA decarboxylases [17]. Both are existing in AviE2. An
aspartate, which is conserved in 4,6-dehydratases [18],
is occupied by a serine (S135) in AviE2. This serine has
been shown to be involved in the decarboxylation pro-
cess of UDP-decarboxylases [17]. To prove the function
of AviE2, the corresponding gene was overexpressed
in E. coli as His-tag fusion protein. Subsequent AviE2
characterization revealed this protein to be a UDP-GlcA-
decarboxylase (Figure 5). The product of the AviE2 reac-
tion was identified as UDP-D-xylose by HPLC-MS
(Figure 6) and by NMR analysis. The chemical shifts mea-
sured in the 1D-spectra were in very good accordance
with the literature [19] and, moreover, have been verified
using the 2D-experiments described in Experimental
Procedures. The 3JH1,H2 coupling constant of 3–3.5 Hz
(lit.: 3.5 Hz) confirmed the a-anomeric configuration of
the UDP-pentose. The identification as UDP-D-xylose
was based on the measured 3JH3,H4 coupling constant
of 9 6 0.5 Hz (lit.: 3JH3,H4(xylose) = 8.9 Hz;
3JH3,H4(arabi-
nose) = 3.4 Hz).
Replacement of the UDP-GlcA substrate with UDP-
Glc or NAD+ with NADP+ yielded no product, indicating
specificity of the reaction for UDP-GlcA and NAD+. The
activity obeyed Michaelis-Menten kinetics with a Km of
w1.2 mM for UDP-GlcA, which is reasonable for this
type of enzyme [14, 15]. The dexcarboxylation of UDP-
D-GlcA to UDP-D-xylose is a common enzymatic step
in the formation of pentoses for the primary metabolism
[19, 20], but has never been described as enzymatic
step in the formation of pentoses for the secondary me-
tabolism in actinomycetes.
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lase indicates that the formation of avilamycin A starts
with the formation of UDP-L-lyxose from UDP-D-
glucose. Thorson and coworkers proposed a similar
biosynthetic pathway to the deoxypentose moieties of
enediyne antitumor antibiotics. They found a UDP-glu-
cose dehydrogenase encoding gene (calS8) in the cali-
cheamicin gene cluster responsible for the conversion
of UDP-D-glucose to UDP-D-GlcA and also a gene en-
coding a putative decarboxylating enzyme (CalS9) [21].
Interestingly, no UDP-glucose dehydrogenase encoding
gene candidate has been detected in the avilamycin
gene cluster so far. The conversion of UDP-D-xylose to
UDP-L-lyxose requires two additional epimerization
steps (Figure 7). There are candidates in the avilamycin
gene cluster (aviQ1, aviQ2, aviQ3) that might be involved
in these biosynthetic steps.
Significance
To our knowledge, this is the first report on avilamycin
A biosynthetic enzymes involved in the formation of
the hexasaccharide biosynthesis. Our data show that
AviGT4 is involved in the formation of the unusual
orthoester linkage between the eurekanate portion
and L-lyxose. Gene inactivation as well as gene ex-
pression and biochemical experiments indicate that
AviE2 is involved in the decarboxylation of UDP-
GlcA to form UDP-D-xylose. Based on the increasing
level of interest in new antibiotics, biosynthetic stud-
ies are of importance and will pave the way for the
formation of novel derivatives in the future.
Experimental Procedures
Feeding Experiments
S. viridochromogenes Tu¨57 was grown on 1% malt extract, 0.4%
yeast extract, and 0.4% glucose (pH adjusted to 7.5) [HA-medium]
at 37ºC and 180 rpm. For avilamycin production, S. viridochromo-
genes Tu¨57 was grown at 28ºC in SG medium containing 2% glu-
cose, 1% soy peptone, 0.1% CaCO3, 20 mM L-valin, and 1 ml of
0.1% CoCl2 (pH adjusted to 7.2). Then 100 mg/l of the U-
13C -glucose
or 1-13C -glucose was added after 24 and 48 hr. The avilamycins
were isolated after 72 hr of cultivation and purified as described
previously [2]. After purification, the substances were analyzed by
13C-NMR.
Bacterial Strains, Plasmids, and Culture Conditions
DNA manipulation was carried out using E. coli XL-1 Blue MRF0
(Stratagene) as the host strain. Before transforming S. viridochro-
mogenes strains, plasmids were propagated in E. coli ET 12567
(dam2, dcm2, hsdS, CmR) [22, 23] to obtain unmethylated DNA.
E. coli strains were grown on Luria-Bertani (LB) agar or liquid medium
containing the appropriate antibiotic. pBluescript SK2 (pBSK2) and
pBC-SK2 were from Stratagene; pUC19 was from New England Bi-
olabs. Plasmid pSP1 [24], conferring erythromycin resistance, was
a kind gift of Dr. S. Pelzer, and pSET152 [25], conferring apramycin
resistance, was obtained from Eli Lilly & Co. The construction of
pSET-1cerm has been described [26].
General Genetic Manipulation, PCR, and Sequence Analysis
Routine methods were performed as described [27]. Isolation of
E. coli plasmid DNA, DNA restriction, DNA modification, and South-
ern hybridization were performed following the manufacturer’s
directions (Amersham Biosciences, Roche Diagnostics, Promega,
Stratagene). Streptomyces protoplast formation, transformation,
and protoplast regeneration were performed as described [28].
PCR was carried out using a GeneAmp PCR System 9700 (Applied
Biosystems). Oligonucleotide primers from Qiagen are listed in the
Supplemental Data. Computer-aided sequence analysis was done
with the DNAsis software package (version 2.1, 1995; Hitachi Soft-
ware Engineering). Database searches were performed with the
BLAST 2.0 program [29] on the server of the National Center for Bio-
technology Information, Bethesda, MD.
Construction of Gene Inactivation Plasmids
aviE2
AviE2, located on a 2.6 kb EcoRI/SacI fragment, was ligated into
pBCSK2 to generate plasmid pBC-aviE2. A unique BamHI restric-
tion site was altered by BamHI restriction and subsequent treatment
with T4 DNA polymerase and religation. DNA sequencing showed
Figure 6. Electrospray Negative Ion Spectra of UDP-GlcA (1) and
UDP-D-Xylose (2)
Besides the UDP-glucuronate peak ([M-H]2 = 579.0), additional
peaks appeared in the negative ion spectrum reflecting the presence
of monosodiated ([M + Na22H]2= 601.0) and disodiated ([M + 2Na2
3H]2 = 623.0) UDP-glucuronate. For UDP-D-xylose, peaks appeared
at ([M-H]2 = 535.0), ([M + Na2 2H]2 = 557.0) and ([M + 2Na2 3H]2 =
578.8.
Figure 7. Hypothetical Biosynthetic Pathway
from UDP-D-Glucose to UDP-L-Lyxose
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aviE2. After restriction with EcoRI and SacI, the insert was trans-
ferred to plasmid pSP1 to generate pSP-aviE2.
aviP
A 3.7 kb SacI fragment containing aviP was ligated in pBSK2. A
unique BsmI restriction site was used for modification by restriction
with BsmI, treatment with T4 DNA polymerase and subsequent re-
ligation of the plasmid. DNA sequencing revealed the deletion of
25 bp in aviP.
After restriction withSacIand XbaI, the insert was ligated inplasmid
pSP1. By restriction with NotI and following religation, the insert was
shortened to 1.8 kb. The resulting construct was named pSP-aviP.
aviD
A 2.85 kb section including the entire reading frame of aviD was am-
plified by PCR. Primers aviD-F1 and aviD-R1, which introduced re-
striction sites for HindIII and BamHI, were used. This PCR fragment
was cloned into pUC19 to give pUC19/aviD. By restriction with SacII
and ligation of the remaining plasmid, a 291 bp fragment was de-
leted out of the gene aviD. The intended alteration was checked
by DNA sequencing using the primer aviD-BS1. The altered 2.57
kb insert of pUC19/aviD-S was excised by HindIII and EcoRI and
was ligated in the PstI and EcoRI sites of pSP1 after generation of
blunt ends by the Klenow enzyme leading to the final inactivation
plasmid pSP1/aviD-S.
aviGT4
A region of 2.8 kb containing aviGT4 was amplified from chromo-
somal DNA using primers aviGT4-F1 and aviGT4-R1. The PCR prod-
uct was ligated into the EcoRI and XbaI sites of pUC19. To shift the
reading frame of aviGT4, the plasmid was linearized by digestion of
a singular NotI site internal to aviGT4 and treated with T4-polymer-
ase to blunt the sticky ends. After religation, the intended alteration
(correct fill-in) was confirmed by DNA sequencing. Finally, the
EcoRI- XbaI- insert was cloned into pSP1, yielding pSP1_aviGT4i.
Construction of Complementation Plasmids for aviE2,
aviGT4, and aviD
aviE2
For generation of the plasmid pSETerm-aviE2 used to complement
the decarboxylase mutant, aviE2 was amplified by PCR. As suitable
restriction sites, EcoRI and XbaI were introduced upstream and
downstream of the gene using oligonucleotide primers aviE2F and
aviE2R. Plasmid pSET-1cerm was digested with MunI and XbaI to
remove urdGT1c, and aviE2 was cloned behind the ermE* promoter
after restriction of the PCR product using EcoRI and XbaI. The re-
sulting complementation plasmid was named pSETerm-aviE2.
aviD
A 5 kb fragment including aviD was cut out of a 7.7 kb SacI fragment
(P2S11) using BamHI and EcoRI. The fragment was cloned into the
BamHI and EcoRI site of pSET152 to yield complementation con-
struct pSET152/aviD.
aviGT4
A 2.8 kb fragment containing aviGT4 was amplified from chromo-
somal DNA using primers aviGT4-F1 and aviGT4-R1. The PCR prod-
uct was digested by EcoRI/XbaI and ligated into pSET-1cerm
restricted by MunI/XbaI to yield pSETermE-aviGT4.
Expression and Purification of AviE2
The aviE2 gene was PCR-amplified using NcoI-modified primer E2A
and EcoRI-modified primer E2B and subcloned into the vector
pRSETb (Invitrogen) to form plasmid pRSET-E2. DNA sequence of
the coding region was confirmed by sequencing (4base lab).
For purification of expressed protein, E. coli strain BL21 (DE3)
pLysS cells (Stratagene), carrying either pRSET-E2 with aviE2 or
the pRSETb vector alone, were grown in NZCYM medium containing
50 mg/ml carbenicillin and 30 mg/ml chloramphenicol to OD600= 0.6.
Protein expression was induced for 4 hr at 28ºC with 1mM isopropyl-
b-D-thiogalactopyranoside. Cells were harvested by centrifugation
and stored at 220ºC. The cell pellet from 100 ml culture was resus-
pended in 4 ml lysis buffer (NaH2PO4 50 mM, NaCl 300 mM, imidazol
10 mM) containing 1 mg/ml lysozyme and stored on ice for 30 min. Af-
ter centrifugation, the supernatant fraction was used for purification.
Protein was bound to Ni-NTA agarose (Qiagen) and loaded on
a column. The column was washed twice with washing buffer con-
taining 20 mM imidazol. The protein was eluted with elution buffercontaining 250 mM imidazol. SDS-PAGE of the starting material
and the eluted fraction is shown in Figure 7.
Decarboxylase Assay
Standard analytical enzyme assays (200 ml) were performed at 23ºC
for 60 min. One incubation mixture contained 40 mM Tris-HCl (pH
7,4), 1mM NAD+, 1 mM UDP-GlcA and 1.3 mg/ml AviE2. Reactions
were stopped by the addition of 200 ml of phenol-chloroform,
vortex-mixed and subjected to centrifugation (14,000 rpm, 5 min,
room temperature). The aqueous phase was reserved, and the or-
ganic phase was reextracted with 160 ml H2O. The two aqueous
phases were pooled and further purification was achieved by
HPLC (Agilent 1100) on a 150 3 4.6 mm quaternary amine-silica
gel ion exchange column (Zorbax 5 mm SAX, Agilent) run at 1.5 ml/
min. After injection, the column was washed for 5 min with mobile
phase A (5% glacial acetic acid in water) and then eluted with a
18 min linear gradient from 12% to 45% with solvent B (0.5 M
NH4HCO3, pH 7 in water) and water. The LC eluent was split (Agilent
splitter) 1:50 with water and transferred to a mass spectrometer
(Agilent). The make-up pump was set to 0.5 ml/min. The mass spec-
trometer consisted of an electrospray chamber and a quadrupole
detector. For NMR analysis, 12.9 mg UDP-GlcA was used in a 10 ml
incubation mixture. After 8 hr, the product was purified by HPLC-
MS, dissolved in water, relyophilized several times, exchanged
twice with 99% D2O, and then subjected to NMR analysis.
ESI- and APCI-MS Analysis
Mass spectrometry of purified gavibamycins A1 and P1 was per-
formed on an Agilent 1100 series system optionally equipped with ei-
ther an ESI or APCI chamber and a quadrupole detector. Samples
were dissolved in 100% CH3CN and directly applied to the ionization
chamber with a 90:10 (CH3CN:H2O) eluent at a flow rate of 0.7 ml/min.
To determine the [M-H]2 molecular ions, ESI spectrometry was car-
ried out using chamber settings as follows: drying gas flow, 12 l/min
(nitrogen); drying gas temperature, 350ºC; nebulize pressure,
50 psig; capillary voltage (negative), 3kV. Samples were analyzed
in the negative ionization mode with a mass range set to 400–1400
Da. For fragmentation analyses, APCI spectrometry was carried
out under the following chamber conditions: drying gas flow, 12 l/min
(nitrogen); drying gas temperature, 350ºC; nebulize pressure,
50 psig; vaporizer temperature, 450ºC; capillary voltage (negative),
3kV; corona current, 25 mA. Samples were analyzed in the negative
ionization mode with a mass range set to 180–1450 Da.
NMR Analysis
The experiments were recorded in DMSO-d6 at 295 K on Bruker
DMX spectrometers (600 and 750 MHz) using 5 mm Shigemi tubes:
1H-1D, 13C-1D, COSY [30], TOCSY [31–33], ROESY [34] (mixing time:
150 ms), HSQC [35], HMBC [36], and HMQC-COSY [37]. All spectra
were assigned using the program SPARKY [38].
Supplemental Data
Supplemental Data are available with this article online at http://
www.chembiol.com/cgi/content/full/12/10/1137/DC1/.
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